February 25, 2020

In a global settlement agreement with states and local entities, Mallinckrodt, the largest generic opioid manufacturer in the United States, has agreed to pay at least $1.6 billion in cash to a trust that would help fund treatment for opioid addiction.  Mallinckrodt also agreed to be subject to stringent injunctive terms, including prohibitions on the marketing of its opioid products and safeguards to prevent them from ending up in the wrong hands.  The pharmaceutical company had earlier paid $35 million to the DOJ for other opioid related charges.  CA AG; FL AG; GA AG; VA AG

Tagged in: Pharma Fraud,